Senhwa Biosciences Advances Study of Silmitasertib in Pediatric Solid Tumors with IND Submission to US FDA
Thursday, 11 July 2024, 21:48
Senhwa Biosciences Advances Study of Silmitasertib
Senhwa Biosciences has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for the Phase I/II clinical study of Silmitasertib (CX-4945) in pediatric patients.
Potential Treatment for Relapsed Refractory Solid Tumors
The study aims to assess the safety and effectiveness of Silmitasertib in addressing the medical needs of children and young adults with challenging solid tumor conditions.
- Significant Milestone: Submission of IND signifies progress towards developing a promising therapy.
- Improving Healthcare: Senhwa's dedication to pediatric oncology highlights a commitment to better patient outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.